8-K: bioAffinity Technologies Reports Strong Q3 Revenue Growth and Expanded CyPath Lung Test Availability

bioAffinity Technologies reported a significant increase in revenue for Q3 2024, driven by expanded sales of its CyPath Lung test and a recent acquisition.

Summary

• bioAffinity Technologies reported $2.4 million in revenue for the third quarter of 2024, a substantial increase compared to $298,000 in the same period last year.
• The company's CyPath Lung test saw a growth rate of over 1,300% in orders during the first nine months of 2024 compared to the entire year of 2023.
• The number of physician offices offering CyPath Lung increased by 75% compared to the second quarter of 2024.
• CyPath Lung was added to the U.S. Federal Supply Schedule, providing access to 1,380 government healthcare facilities.
• The company reaffirmed its $9.6 million revenue forecast for its Precision Pathology subsidiary for 2024.
• A study concluded that adding CyPath Lung to the standard of care could save an average of $2,773 per patient, totaling $379 million in 2022.
• The company closed a $2.7 million registered direct offering and private placement to fund growth.
• The net loss for the quarter was $2.0 million, or $0.16 per share, an improvement from a net loss of $2.3 million, or $0.26 per share, in the same period last year.
• Cash and cash equivalents were $0.8 million as of September 30, 2024, compared to $2.8 million at the end of 2023.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, increased market penetration, and a successful capital raise. However, the net loss and decrease in cash reserves temper the overall optimism.

Positives

• The company experienced substantial revenue growth in Q3 2024, reaching $2.4 million.
• CyPath Lung test orders have seen a dramatic increase, growing over 1,300% in the first nine months of 2024 compared to the full year 2023.
• The number of physician offices offering CyPath Lung increased by 75% compared to the previous quarter.
• The addition of CyPath Lung to the U.S. Federal Supply Schedule expands access to the test for veterans.
• The company has secured a patent in Japan for its method of predicting lung disease.
• The company successfully raised $2.7 million through a registered direct offering and private placement.
• The net loss improved compared to the same period last year.

Negatives

• The company reported a net loss of $2.0 million for the third quarter of 2024.
• Cash and cash equivalents decreased to $0.8 million as of September 30, 2024, from $2.8 million at the end of 2023.
• Selling, general and administrative expenses increased to $2.4 million for the third quarter of 2024, compared to $2.0 million for the comparable period in 2023.

Risks

• The company's ability to accelerate sales growth and expand operations is subject to various risks and uncertainties.
• The company's ability to meet rising demand and accelerate its nationwide growth is not guaranteed.
• The company's ability to advance its mission to enhance patient outcomes through groundbreaking, noninvasive cancer diagnostics is subject to risks.
• The company's ability to address the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments is subject to risks.

Future Outlook

The company anticipates accelerating sales growth in the coming quarters, broadening access to CyPath Lung, expanding operations, and strengthening its market position. They aim to enhance patient outcomes through noninvasive cancer diagnostics.

Management Comments

• We are pleased with the continued progress we achieved in the third quarter, highlighted by a 75% growth in the number of physician offices signing on to offer CyPath Lung.
• This significant expansion not only reflects the increasing recognition of our tests value in early lung cancer detection but also lays a strong foundation for accelerating sales growth in the coming quarters.
• With CyPath Lung now being used in 11 states and its recent addition to the U.S. Federal Supply Schedule, we are making meaningful strides in broadening access to this innovative diagnostic tool.
• Our focus remains on expanding our operations and strengthening our foothold in this rapidly growing market.
• Our strategic approach in Texas has resulted in a robust sales and support infrastructure that has us well-equipped to meet rising demand and accelerate our nationwide growth.
• As we look toward the future, we are confident that these efforts will not only fuel our success but also advance our mission to enhance patient outcomes through groundbreaking, noninvasive cancer diagnostics.

Industry Context

The announcement reflects a growing trend in the healthcare industry towards non-invasive diagnostic tests for early cancer detection. The expansion of CyPath Lung into multiple states and its inclusion in the Federal Supply Schedule indicates a move towards broader adoption of such technologies.

Comparison to Industry Standards

• The 1,300% growth in CyPath Lung orders is significantly higher than the average growth rate for diagnostic tests in the market, suggesting strong market acceptance.
• The addition of CyPath Lung to the Federal Supply Schedule is a significant achievement, comparable to other successful medical device companies that have secured government contracts.
• The economic study showing potential cost savings of $2,773 per patient is a strong value proposition, similar to other cost-effective diagnostic solutions in the market.
• The company's revenue growth is impressive compared to other early-stage biotech companies, but the net loss is typical for companies in this phase of development.

Management Changes

Stakeholder Impact

• Shareholders will likely view the revenue growth and expanded market access positively.
• Employees may benefit from the company's growth and expansion.
• Customers (physicians and patients) will have increased access to the CyPath Lung test.
• Suppliers may see increased demand for their products and services.
• Creditors may be more confident in the company's ability to repay debts due to increased revenue.

Next Steps

• The company plans to continue expanding its operations and strengthening its market position.
• The company will focus on accelerating sales growth of CyPath Lung.
• The company will continue to advance new product development initiatives.

Key Dates

Keywords

CyPath Lung, lung cancer, diagnostics, revenue, biotechnology, Precision Pathology, Federal Supply Schedule, noninvasive, flow cytometry, early-stage cancer